Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AMD vs AQST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

AMD Overall Winner 6-Pillar Tally: AMD 5 – 1 AQST Matrix Metrics: AMD 8 – 2 AQST

As of Nov 20, 2026, Advanced Micro Devices (AMD) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMD carries a Unified Composite Score of 62.6/100 (BUY) at $424.39 (24.1x Forward P/E, 17.8% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin).

  • Technical & Structure Timing Caution: AMD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.4); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMD vs AQST
AMD NASDAQ Head-to-Head Winner
Advanced Micro Devices
Semiconductors & Related Devices
$424.39
-13.25% 1D
Market Cap $809.6B
TTM Revenue $45.4B
Forward P/E 24.1x
Beta / 30D Vol 3.65β · 124% Vol
Unified Composite Score
62.6 / 100 BUY
Tech 50.0 Fund 60.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.4 · SMA20: $509.08 · SMA50: $553.10
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23

6-Pillar Scorecard Institutional Category Breakdown (AMD 5 – 1 AQST)

Columns: Metric · AMD · AQST
1. Valuation Multiples AMD
Forward P/E 24.1x N/M
Trailing P/E 104.5x N/M
PEG Ratio 0.47x N/M
EV / Revenue 17.9x 8.9x
2. Growth & Scale AMD
Revenue Growth (YoY) +44.7% -41.0%
Earnings Growth (YoY) +93.8% +0.0%
TTM Revenue (USD) $45.4B $49M
Market Cap $809.6B $465.7M
3. Profitability & Quality AMD
Gross Margin 56.0% 65.3%
Operating Margin 17.8% -114.1%
Net Profit Margin 16.8% -162.3%
Return on Equity (ROE) 12.0% 0.0%
4. Balance Sheet & Cash Flow AMD
Cash Generation (TTM) $7.06B -$41M
Cash Flow Margin 15.5% -83.3%
Net Cash / Leverage $1.51B Net Debt (0.13x D/E) $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 87.2% (11th %ile) 87.9% (64th %ile)
Put/Call OI Skew 1.31x (Put-Skewed) 0.98x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMD
OpEx & R&D Intensity 38.2% of Rev ($17.4B) N/A
90D R&D Disclosures 7 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role AI Accelerator & Server Chiplet Designer Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMD (8) vs AQST (2)
Institutional Metric AMD AQST Criterion Row Edge
Market Capitalization
Scale
$809.6B $465.7M Larger Scale AMD
Trailing P/E Ratio
Valuation
104.5x N/M Lower Multiple AMD
Forward P/E Ratio
Valuation
24.1x N/M Lower Multiple AMD
Revenue Growth (YoY)
Growth
+44.7% -41.0% Higher Growth AMD
Operating Margin (TTM)
Profitability
17.8% -114.1% Higher Margin AMD
Net Profit Margin
Profitability
16.8% -162.3% Higher Margin AMD
Return on Equity (ROE)
Capital Efficiency
12.0% 0.0% Higher ROE AMD
52-Week Range Position
Momentum
50% ($188–$659) 14% ($3–$7) Stronger Trend AMD
Beta / 30D Volatility
Risk Regime
3.65β · 124% Vol 0.89β · 56% Vol Lower Realized Risk AQST
Unified Institutional Score
Composite Signal
62.6 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$45.4B $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
56.0% 65.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 17.9x EV/Rev N/M PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.06B ($1.51B Net Debt (0.13x D/E)) -$41M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +0.23 pp
AMD: -16.45% · AQST: -16.22%
3M Horizon AMD +20.84 pp
AMD: -7.08% · AQST: -27.92%
6M Horizon AMD +6.8 pp
AMD: -9.22% · AQST: -16.02%
1Y Horizon AMD +130.49 pp
AMD: +89.84% · AQST: -40.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AMD Revenue AQST Revenue AMD Op. Margin AQST Op. Margin Margin Leader
FY2018 $6.47B $70M 7.0% -72.6% AMD
FY2019 $6.73B $50M 9.4% -100.1% AMD
FY2020 $9.76B $50M 14.0% -93.6% AMD
FY2021 $16.4B $50M 22.2% -68.2% AMD
FY2022 $23.6B $50M 5.4% -88.2% AMD
FY2023 $22.7B $50M 1.8% -29.9% AMD
FY2024 $25.8B $60M 7.4% -53.5% AMD
FY2025 $34.6B $40M 10.7% -159.5% AMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMD CONSOLIDATION
107d in phase · OBV DISTRIBUTION
Current IV 87.2%
IV Percentile 11th %ile
Put/Call OI Skew 1.31x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor $430.00
Call Wall Magnet $500.00
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Put Floor: $430.00 (1.3%) Spot: $424.39 Call Magnet: $500.00 (+17.8%)
  • Extended consolidation (107 days)
  • IV expanding (+13.7%) but put wall rising - pre-earnings positioning (neutral)
  • Near put wall support ($430)
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $504.28 · IV 73.5%

AMD Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($50,428)

Compare $50,428 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 73.5% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $510 / $580 Bull Call Spread

Buy 1x $510C · Sell 1x $580C · 31d

Net Entry $2,436 Debit
T+5d @ +5% Move +$583 (+24%)
Max Risk / Buffer $2,436 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $440 / $410 Bull Put Spread

Sell 1x $440P · Buy 1x $410P · 31d

Net Entry $731 Credit
Max Credit / Yield +$731 (+32.2% RoM)
Max Risk / Buffer -14.2% Cushion ($2,269 Mgn)
5d Edge & Liquidity 76% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $450P / $520-$590C Seagull

Sell 1x $450P · Buy 1x $520/$590C · 31d

Net Entry $52 Debit
T+5d @ +5% Move +$1,463 (+21.3% RoM)
Max Risk / Buffer -10.8% Put Cushion ($6,861 Mgn)
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMD Moat Profile Concentrated Oligopoly Moat
AI Accelerator & Server Chiplet Designer
Data center GPU accelerators and server CPU chiplets scale directly with upstream leading-edge foundry utilization and cloud server integration.
OpEx & R&D Reinvestment 38.2% of Rev ($17.4B)
90D Engineering Disclosures 7 Published · LLM Efficiency / Architecture
Mapped Supply-Chain Ecosystem (18 partners):
Taiwan Semiconductor Manufacturing Company GlobalFoundries Samsung Electronics ASE Technology Holding
Active 90D Technical Topics:
Edge AI / Inference Chips Hardware-Agnostic ML Compilers Inference Serving / Speculative Decoding KV-Cache / Attention Memory Compression Mixture-of-Experts / Sparse Models
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMD vs AQST Key Questions & Quantitative Answers

As of Nov 20, 2026, Advanced Micro Devices (AMD) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AMD carries a Unified Composite Score of 62.6/100 (BUY) at $424.39 (24.1x Forward P/E, 17.8% operating margin), whereas AQST carries 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin). Technical & Structure Timing Caution: AMD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.4); meanwhile AQST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMD leads the Growth & Scale pillar: AMD posts +44.7% YoY revenue growth and +93.8% YoY earnings growth on $45.4B TTM revenue (56.0% gross margin, 17.8% operating margin), compared with AQST at -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AMD cumulative revenue shifted +435.4% while AQST shifted -42.9%. In operating R&D and SG&A reinvestment, AMD deploys 38.2% of Rev ($17.4B) (7 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQST.

AMD screens cheaper on headline valuation multiples. AMD trades at 24.1x Forward P/E, 104.5x Trailing P/E, 0.47x PEG, and 17.9x EV/Revenue (15.5% FCF margin), whereas AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMD (12.0% ROE) versus AQST (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AMD carries 87.2% implied volatility (11th %ile, Compressed (<25th %ile)), a 1.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.65β · 124% Vol realized risk). By comparison, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.